Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000598246 | SCV000707470 | uncertain significance | not provided | 2018-05-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000806334 | SCV000946326 | benign | Bethlem myopathy 1A | 2024-08-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002531079 | SCV003740915 | uncertain significance | Inborn genetic diseases | 2024-08-14 | criteria provided, single submitter | clinical testing | The c.550G>A (p.A184T) alteration is located in exon 3 (coding exon 2) of the COL6A3 gene. This alteration results from a G to A substitution at nucleotide position 550, causing the alanine (A) at amino acid position 184 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004737871 | SCV005364246 | uncertain significance | COL6A3-related disorder | 2024-04-03 | no assertion criteria provided | clinical testing | The COL6A3 c.550G>A variant is predicted to result in the amino acid substitution p.Ala184Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0040% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |